Company intelligence / Profile preview

Onyx Therapeutics

South San Francisco, California, United Statesonyxtherapeutics.ca ↗

Ownership: Private
Development stage: Commercial

Overview

Onyx Pharmaceuticals developed cancer treatments including Kyprolis (carfilzomib) for multiple myeloma and co-marketed Nexavar with Bayer for liver and kidney cancer. The company was acquired by Amgen in 2013 for approximately $10.4 billion.

Therapeutic areas: OncologyImmunologyHematology
Modalities: Small molecule drugsSynthetic peptides
Industry: Biotech

Drug pipeline

3 assets

carfilzomib

Commercial

Indications: Multiple myeloma

2 more assets in the full pipeline.

Request access →

Partnerships

Bayer HealthCare Pharmaceuticals (co-development and co-marketing of Nexavar)

Beyond the preview

Go deeper on Onyx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onyx Therapeutics.

Explore the full profile